100-Year Human Aging Study
Key claim: The 100-Year Human Aging Study will longitudinally track comprehensive multi-system health measurements until death to determine which markers, alone or in combination, predict all-cause and cause-specific mortality, incident serious disease, and functional disability.
Abstract
The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed clinical sites, mobile clinical sites, and an online participation pathway (current and future) to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.
Why this matters
Precision geromedicine and the broader longevity-clinic economy currently market interventions against surrogate biomarkers (epigenetic clocks, multi-omic gerotypes, functional composites) whose link to hard outcomes — death, incident disease, disability — is largely inferred. A prospective cohort followed to death is the infrastructure needed to tell which of those markers actually track the endpoints the field claims to move; until it reads out, the surrogate-to-outcome gap remains the central unresolved question behind most protocols tracked in this area.